Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 9/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 3/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009592 | 0.86 | NR1H3 (0.38) | PTGS1NR1H3PTPN1 | |
| SCHEMBL267558 | 0.83 | KARS1 (0.38) | PTGS1NR1H3PTPN1 | |
| SCHEMBL6009546 | 0.83 | KARS1 (0.38) | PTGS1NR1H3PTPN1 | |
| SCHEMBL12704621 | 0.83 | NR1H3 (0.58) | PTGS1NR1H3PTPN1RXRARXRB | |
| SCHEMBL6008298 | 0.83 | NR1H3 (0.58) | PTGS1NR1H3PTPN1RXRARXRB | |
| SCHEMBL266932 | 0.83 | NR1H3 (0.58) | PTGS1NR1H3PTPN1RXRARXRB | |
| SCHEMBL14610508 | 0.83 | NR1H3 (0.58) | PTGS1NR1H3PTPN1RXRARXRB | |
| SCHEMBL267305 | 0.83 | NR1H3 (0.58) | PTGS1NR1H3PTPN1RXRARXRB | |
| SCHEMBL12704708 | 0.83 | NR1H3 (0.58) | PTGS1NR1H3PTPN1RXRARXRB | |
| SCHEMBL280314 | 0.82 | PTGS1 (0.44) | PTGS1NR1H3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912932-B1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-A MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS INC (US) | 2012-05-02 | — | — | EP | disclosed |
| US-8133915-B2 | Interleukin-1 and tumor necrosis factor-α modulators; syntheses of such modulators and methods of using such modulators | NEREUS PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110160309-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160309-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | IL1A, IL1B, TNF | PTGS1 20/4885NR1H3 3538/4885PTPN1 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.